Ahmedabad-based Cadila Pharmaceuticals has announced the launch of Biscado (Bisoprolol), marking its foray into the dynamic and fast-growing field of beta-blocker therapy, a vital component in the treatment of cardiovascular diseases.
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure, angina (chest pain), and chronic heart failure. By reducing heart rate and blood pressure, it eases the strain on the heart and has been shown to significantly improve survival and reduce hospitalisations in heart failure patients.
The relevance of Biscado in India is particularly significant. Indians are predisposed to higher sympathetic activity and elevated resting heart rates, which are well-recognised predictors of poor cardiovascular outcomes. Studies have shown that an increase of just 10 beats per minute in resting heart rate is associated with a 20% increase in the risk of cardiovascular death.
Biscado is supported by extensive clinical research, including the landmark CIBIS-II (Cardiac Insufficiency Bisoprolol Study), which demonstrated a 34% reduction in all-cause mortality, a 44% reduction in sudden cardiac death, and a 36% reduction in hospitalisation due to worsening heart failure.
Other studies have reinforced Bisoprolol’s superiority with a 20% lower risk of mortality compared to Metoprolol Succinate and better mortality outcomes than Carvedilol in chronic heart failure patients. A Total Ischemic Burden Bisoprolol Study (TIBBS) study showed that in stable angina, Biscado users had lower rates of death, myocardial infarction, and hospitalisation, versus patients treated with calcium channel blockers.
Beyond its mono-therapy form, Biscado will be introduced in Fixed-Dose Combinations with other antihypertensive agents, covering the entire spectrum of cardiovascular management.
